Search results for "Genou"

showing 10 items of 610 documents

Lack of plasmic beta-endorphin response to a gastronomic meal in healthy humans.

1991

Abstract In order to study the relationship between the endogenous opiate system and food intake in man, plasma concentrations of beta-endorphin were measured in ten healthy subjects. Time course of beta-endorphinemia was compared under the following conditions: basal (fasting), after an injection of pentagastrin (6 μg/kg), or after a gastronomic meal. No changes in plasma beta-endorphin or ACTH concentrations were observed with pentagastrin nor after the meal, despite the combination of very high sensory pleasure with intake of a very large amount of food. It is concluded that blood beta-endorphin concentration is not a sensitive index of the effects of food intake on the endogenous opioid…

AdultBlood GlucoseMaleendocrine systemmedicine.medical_specialtyHungerAppetiteExperimental and Cognitive PsychologyPeptide hormoneBehavioral Neurosciencechemistry.chemical_compoundEatingInternal medicinemedicineHumansPalatabilityEndogenous opioidMealbusiness.industrydigestive oral and skin physiologybeta-EndorphinPentagastrinAffectEndocrinologychemistryBasal (medicine)TasteReceptors Opioidbeta-EndorphinOpiatebusinessArousalEnergy Intakehormones hormone substitutes and hormone antagonistsmedicine.drugPhysiologybehavior
researchProduct

Results of an Open Clinical Trial of Brofaromine (CGP 11 305 A), a Competitive, Selective, and Short-Acting Inhibitor of MAO-A in Major Endogenous De…

1987

In an open clinical trial the authors treated 18 hospitalized patients suffering from endogenous depression with brofaromine (CGP 11305A), a competitive, selective, and short-acting inhibitor of type A monoamine oxidase (MAO). Four patients were defined as good responders, as they had a final HAMD score of between 0 and 7 points. Four patients were judged as improved, with final HAMD scores of between 8 and 15 points, while the remaining eight patients failed to respond (final HAMD score greater than or equal to 16 points). The major observations were a beneficial influence on drive in most patients, while paranoid symptoms worsened markedly, rendering the substance contraindicated in psych…

AdultBlood PlateletsMaleSerotoninMonoamine Oxidase Inhibitorsmedicine.medical_treatmentSleep REMTyraminePsychotic depressionPharmacologyPersonality AssessmentDexamethasonechemistry.chemical_compoundPiperidinesBrofaromineHamdmedicineHumansPharmacology (medical)Monoamine OxidaseDepression (differential diagnoses)AgedDepressive DisorderChemotherapybiologyElectroencephalographyGeneral MedicineMiddle Agedmedicine.diseaseClinical trialPsychiatry and Mental healthchemistryEndogenous depressionbiology.proteinFemaleMonoamine oxidase APsychologyPharmacopsychiatry
researchProduct

Expression of host defense scavenger receptors in spondylarthropathy

2001

Objective Reactive arthritis (ReA) is postulated to be caused by a defective host defense against gram-negative bacteria. HLA–B27 could play a role in this process, but does not account for the many HLA–B27 negative patients. The objective of this study was to test the expression of 3 macrophage scavenger receptors (SRs) that are responsible for innate immunity against gram-negative bacteria: SR class A type I (SR-AI), SR-AII, and the macrophage receptor with collagenous structure (MARCO). We postulate that defects in such receptors might also contribute to the host risk factors that increase the predisposition to ReA and perhaps other subtypes of spondylarthropathy (SpA). Methods Periphera…

AdultCD36 AntigensMalemusculoskeletal diseasesCellular immunityAdolescentInflammatory arthritisImmunologyPeripheral blood mononuclear cellArthritis ReactiveImmune systemRheumatologyProhibitinsSynovial FluidmedicineImmunology and AllergySynovial fluidHumansPharmacology (medical)Spondylitis AnkylosingRNA MessengerScavenger receptorReceptors ImmunologicDNA PrimersReceptors LipoproteinReceptors Scavengerbusiness.industryReverse Transcriptase Polymerase Chain ReactionMacrophagesSynovial MembraneMembrane ProteinsScavenger Receptors Class AMiddle AgedScavenger Receptors Class Bmedicine.diseaseMacrophage receptor with collagenous structuremedicine.anatomical_structureImmunologySalmonella InfectionsLeukocytes MononuclearFemaleSynovial membranebusinessArthritis and rheumatism
researchProduct

CD10 and HHF35 actin in the differential diagnosis between Collagenous Spherulosis and Adenoid-Cystic Carcinoma of the breast

2012

Collagenous Spherulosis (CS) and Adenoid-Cystic Carcinoma (AdCC) of the breast consist of cribriform proliferations of epithelial and myoepithelial cells with an immunophenotypic overlap of some myoepithelial markers, such as p63 and smooth muscle actin (SMA). To our knowledge, CD10 and HHF35 actin have not been assessed in the differential diagnosis of these two breast lesions. We performed an immunohistochemical study on 6 cases of CS and 9 cases of AdCC. We found CD10, muscle-specific actin (HHF35), Estrogen and Progesterone receptors (ER and PR) to be strongly expressed in CS, but not in AdCC; C-kit was diffusely positive in AdCC and scanty in CS; SMA, p63 and Cytokeratine 5/6 (CK5/6) w…

AdultCell typePathologymedicine.medical_specialtyCollagenous SpherulosiAdenoid cystic carcinomaBreast NeoplasmsSettore MED/08 - Anatomia PatologicaHistogenesisBiologyMyoepitheliomaAdenoid-Cystic CarcinomaPathology and Forensic MedicineDiagnosis DifferentialImmunophenotypingimmune system diseasesBiomarkers TumormedicineCarcinomaHumansBreastAgedRetrospective StudiesMyoepithelial cellBreast; Collagenous Spherulosis; Adenoid-Cystic Carcinoma; CD10; HHF35Cell BiologyMiddle Agedmedicine.diseaseCarcinoma Adenoid CysticActinsCollagenous spherulosisCD10ImmunohistochemistryFemaleNeprilysinHHF35Breast Collagenous Spherulosis Adenoid-Cystic Carcinoma CD10 HHF35CollagenPathology - Research and Practice
researchProduct

Genesis of variant Philadelphia chromosome translocations in chronic myelocytic leukemia.

2003

The Philadelphia (Ph) chromosome is found in more than 90% of chronic myelocytic leukemia (CML) patients. In most cases, it results from the reciprocal t(9;22)(q34;q11), with the ABL proto-oncogene from 9q34 fused to the breakpoint cluster region (BCR) locus on 22q11. In 5%-10% of patients with CML, the Ph chromosome originates from variant translocations, involving various breakpoints in addition to 9q34 and 22q11. In our investigation, three CML cases with complex Ph translocations have been analyzed by G-banding and fluorescence in situ hybridization (FISH). FISH with breakpoint-spanning probes for the BCR and ABL genes revealed information about the genesis of complex Ph translocations.…

AdultGenetic MarkersMaleCancer Researchmedicine.medical_specialtyChromosomes Human Pair 22Chromosomal translocationLocus (genetics)BiologyPhiladelphia chromosomeProto-Oncogene MasTranslocation Genetichemic and lymphatic diseasesLeukemia Myelogenous Chronic BCR-ABL PositiveGeneticsmedicineHumansPhiladelphia ChromosomeMolecular BiologyIn Situ Hybridization FluorescenceGeneticsABLmedicine.diagnostic_testChromosomes Human Pair 11BreakpointCytogeneticsbreakpoint cluster regionGenetic VariationMiddle Agedmedicine.diseaseChromosome BandingKaryotypingFemaleChromosomes Human Pair 9Fluorescence in situ hybridizationCancer genetics and cytogenetics
researchProduct

The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity

2022

AimsTyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverseevents. So far, the Systematic Coronary Risk Evaluation (SCORE) charts of the European Society of Cardiology (ESC) have beenused to identify cancer patients at increased cardiovascular risk. The primary aim of our study was to evaluate the usefulnessof the new cardiovascular risk assessment model proposed by the Cardio-Oncology Study Group of the Heart Failure Associ-ation (HFA) of the ESC in collaboration with the International Cardio-Oncology Society (ICOS) to stratify the cardiovascular riskin CML patients, compared with SCORE risk charts. The secondary aim was to establish…

AdultHeart FailureMaleAspirinMiddle AgedRisk AssessmentCardio-oncology Cardiovascular prevention Chronic myeloid leukaemia Nilotinib Ponatinib Cardiovascular toxicityCardiotoxicityInducible T-Cell Co-Stimulator ProteinLeukemia Myelogenous Chronic BCR-ABL PositiveChronic DiseaseHumansFemaleCardiology and Cardiovascular MedicineAgedRetrospective StudiesESC Heart Failure
researchProduct

Inter-individual variation of the urinary steroid profiles in Swedish and Norwegian athletes.

2020

The steroidal module of the Athlete Biological Passport (ABP) aims to detect doping with endogenous steroids, e.g. testosterone (T), by longitudinally monitoring several biomarkers. These biomarkers are ratios combined into urinary concentrations of testosterone and metabolically related steroids. However, it is evident after 5 years of monitoring steroid passports that there are large variations in the steroid ratios complicating its interpretation. In this study, we used over 11000 urinary steroid profiles from Swedish and Norwegian athletes to determine both the inter- and intra-individual variations of all steroids and ratios in the steroidal passport. Furthermore, we investigated if th…

AdultMaleAgingUrinary systemmedicine.medical_treatmentPharmaceutical SciencePhysiologyUrineNorwegian01 natural sciencesAnalytical ChemistrySteroid03 medical and health sciencesYoung Adult0302 clinical medicineAnabolic AgentsmedicineEnvironmental ChemistryHumans030216 legal & forensic medicineLongitudinal StudiesSpectroscopyTestosteroneUrine Specimen CollectionDoping in SportsSwedenSex CharacteristicsbiologyAthletesbusiness.industryNorway010401 analytical chemistryConfoundingbiology.organism_classificationlanguage.human_language0104 chemical sciencesCircadian RhythmSubstance Abuse DetectionEndogenous steroidslanguageFemaleSteroidsSeasonsbusinessBiomarkersSportsDrug testing and analysisREFERENCES
researchProduct

The Endogenous Opioid System Is Not Involved in Modulation of Opioid-Induced Hyperalgesia

2009

Abstract Some recent studies suggested a role of the endogenous opioid system in modulating opioid-induced hyperalgesia (OIH). In order to test this hypothesis, we conducted a prospective randomized, placebo-controlled, 2-way crossover study in healthy human volunteers. We utilized a well-established model of inducing OIH after a brief exposure to the μ-opioid agonist remifentanil using intradermal electrical stimulation. Patients were exposed to a randomized 90-minute infusion of remifentanil or saline placebo during 2 separate occasions. Development of OIH was quantified using changes in the average radius of the area of secondary hyperalgesia generated by electrical pain stimulation. A 2…

AdultMaleAgonistmedicine.drug_classNarcotic AntagonistsRemifentanilBlood PressureStimulationPharmacologyPlaceboRemifentanilYoung AdultDouble-Blind MethodPiperidinesHeart RatemedicineHumansOpioid-induced hyperalgesiaPain MeasurementEndogenous opioidCross-Over StudiesNaloxonebusiness.industryMiddle AgedAnalgesics OpioidAnesthesiology and Pain MedicineNeurologyOpioidHyperalgesiaAnesthesiaHyperalgesiaNeurology (clinical)medicine.symptombusinessmedicine.drugThe Journal of Pain
researchProduct

Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia.

2008

Therapeutic effects of haematopoietic stem cell transplantation are not limited to maximal chemoradiotherapy and subsequent bone marrow regeneration, but include specific as well as unspecific immune reactions known as graft-versus-leukaemia (GvL) effects. Specific immune reactions are likely to be particularly relevant to the long-term treatment of diseases, such as chronic myeloid leukaemia (CML), in which residual cells may remain quiescent and unresponsive to cytotoxic and molecular therapies for long periods of time. Specific GvL effects result from the expression on leukaemic cells of specific tumour-associated antigens (TAAs) in the context of HLA proteins. As human leukocyte antigen…

AdultMaleCancer ResearchDNA ComplementaryT-LymphocytesAntigen-Presenting CellsEnzyme-Linked Immunosorbent AssayHuman leukocyte antigenBiologyAntigenhemic and lymphatic diseasesLeukemia Myelogenous Chronic BCR-ABL PositivemedicineCytotoxic T cellHumansIn Situ Hybridization FluorescenceReverse Transcriptase Polymerase Chain ReactionHematologyNM23 Nucleoside Diphosphate Kinasesmedicine.diseaseTransplantationHaematopoiesismedicine.anatomical_structureOncologyImmunologyBone marrowStem cellChronic myelogenous leukemiaLeukemia
researchProduct

Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980-2009.

2014

The treatment of chronic myeloid leukemia (CML) has seen several major advances over the past 30 years, notably with the introduction of interferon followed by Bcr-Abl tyrosine kinase inhibitors. We analyzed trends in the incidence of CML and patient survival in France. All cases recorded in five population-based registries between 1980 and 2009 were included. European (ESR) and world (WSR) standardized incidence rates as well as relative survival (RS) rates were estimated. We analyzed data for 781 patients (9863/3: 13.6%; 9875/3: 82.2%; 9876/3: 4.2%). ESR was 1.02 [95% confidence interval (CI) = 0.93-1.11] and WSR was 0.81 [95% CI = 0.72-0.90]. The five RS rates among patients with Philade…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPopulation03 medical and health sciencesYoung Adult0302 clinical medicinehemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansRegistrieseducationChildSurvival analysisAgedAged 80 and overeducation.field_of_studyPhiladelphia Chromosome PositiveRelative survivalbusiness.industryIncidence (epidemiology)IncidenceInfant NewbornMyeloid leukemiaCancerInfantHematologyMiddle Agedmedicine.diseaseSurvival AnalysisConfidence interval3. Good healthOncology030220 oncology & carcinogenesisChild PreschoolPopulation SurveillanceImmunologyDisease ProgressionFemaleFrancebusiness030215 immunologyFollow-Up StudiesLeukemialymphoma
researchProduct